About Anavex Life Sciences (NASDAQ:AVXL)
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system (CNS) diseases. The Company's SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer's disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Industry, Sector and Symbol
Trailing P/E Ratio-7.35294117647059
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book4.39
Return on Equity-69.24%
Return on Assets-62.66%
Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions
What is Anavex Life Sciences' stock symbol?
Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."
How were Anavex Life Sciences' earnings last quarter?
Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.09) EPS for the quarter. View Anavex Life Sciences' Earnings History.
When will Anavex Life Sciences make its next earnings announcement?
Where is Anavex Life Sciences' stock going? Where will Anavex Life Sciences' stock price be in 2018?
2 brokers have issued twelve-month price objectives for Anavex Life Sciences' shares. Their predictions range from $5.00 to $15.00. On average, they anticipate Anavex Life Sciences' share price to reach $10.00 in the next year. View Analyst Ratings for Anavex Life Sciences.
What are Wall Street analysts saying about Anavex Life Sciences stock?
Here are some recent quotes from research analysts about Anavex Life Sciences stock:
- 1. Maxim Group analysts commented, "We have increased our therapeutic rate cut in our model to 90%, from 75% – taking our price target to $5, from $14, which is still substantially higher versus the current stock price – due to a combination of factors which include: ○ The trial was delayed (biomarkers) and will take time and money. While the company has $28M in capital today, we believe a lot more capital will be needed as the next phases of clinical development get underway, ○ When will we see meaningful clinical data that can convince both KOL’s and Industry experts that the company may have a drug? It will take time." (2/8/2018)
- 2. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (9/26/2017)
Who are some of Anavex Life Sciences' key competitors?
Some companies that are related to Anavex Life Sciences include XOMA (XOMA), NAPEC (NPC), ContraFect (CFRX), Medgenics (GNMX), Trillium Therapeutics (TRIL), Concordia International (CXR), Soligenix (SNGX), Windtree Therapeutics (WINT), Mateon Therapeutics (MATN), Affymax (AFFY), Tetralogic Pharmaceuticals (TLOG), Cubist Pharmaceuticals (CBST), Idenix Pharmaceuticals (IDIX) and Onyx Pharmaceuticals (ONXX).
Who owns Anavex Life Sciences stock?
Anavex Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Park West Asset Management LLC (6.09%), Bank of New York Mellon Corp (0.40%), Deutsche Bank AG (0.19%) and Millennium Management LLC (0.10%). View Institutional Ownership Trends for Anavex Life Sciences.
Who sold Anavex Life Sciences stock? Who is selling Anavex Life Sciences stock?
Who bought Anavex Life Sciences stock? Who is buying Anavex Life Sciences stock?
How do I buy Anavex Life Sciences stock?
Shares of Anavex Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anavex Life Sciences' stock price today?
One share of Anavex Life Sciences stock can currently be purchased for approximately $2.50.
How big of a company is Anavex Life Sciences?
Anavex Life Sciences has a market capitalization of $111.43 million. The biotechnology company earns $-13,460,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Anavex Life Sciences employs 10 workers across the globe.
How can I contact Anavex Life Sciences?
Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]
MarketBeat Community Rating for Anavex Life Sciences (AVXL)MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Anavex Life Sciences (NASDAQ:AVXL) Earnings History and Estimates Chart
Anavex Life Sciences (NASDAQ AVXL) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2018|| || || || || || || || |
Anavex Life Sciences (NASDAQ:AVXL) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.42 EPS
Dividend History for Anavex Life Sciences (NASDAQ:AVXL)
No dividend announcements for this company have been tracked by MarketBeat.com
Anavex Life Sciences (NASDAQ AVXL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 22.68%
Anavex Life Sciences (NASDAQ AVXL) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/24/2017||Christopher U Missling||CEO||Buy||375||$4.92||$1,845.00||1,011,875|| |
|10/19/2017||Christopher U Missling||Insider||Buy||375||$4.49||$1,683.75||1,011,500|| |
|10/17/2017||Christopher U Missling||Insider||Buy||375||$4.27||$1,601.25|| |
|10/13/2017||Christopher U Missling||Insider||Buy||750||$4.22||$3,165.00|| |
|10/5/2017||Christopher U Missling||Insider||Buy||375||$4.30||$1,612.50|| |
|10/2/2017||Christopher U Missling||Insider||Buy||375||$4.20||$1,575.00||1,009,625|| |
|9/28/2017||Christopher U Missling||Insider||Buy||375||$4.21||$1,578.75||1,009,250|| |
|9/26/2017||Christopher U Missling||Insider||Buy||375||$3.88||$1,455.00||1,008,875|| |
|9/20/2017||Christopher U Missling||Insider||Buy||375||$4.23||$1,586.25||1,008,500|| |
|9/18/2017||Christopher U Missling||Insider||Buy||375||$4.40||$1,650.00||1,008,125|| |
|9/14/2017||Christopher U Missling||Insider||Buy||375||$4.58||$1,717.50||1,007,750|| |
|9/11/2017||Christopher U Missling||Insider||Buy||375||$4.81||$1,803.75||1,007,375|| |
|9/7/2017||Christopher U Missling||Insider||Buy||375||$4.76||$1,785.00||1,007,000|| |
|9/5/2017||Christopher U Missling||Insider||Buy||375||$4.90||$1,837.50||1,006,625|| |
|8/31/2017||Christopher U Missling||Insider||Buy||375||$4.48||$1,680.00||1,006,250|| |
|8/28/2017||Christopher U Missling||Insider||Buy||375||$4.44||$1,665.00||1,005,875|| |
|8/24/2017||Christopher U Missling||Insider||Buy||375||$4.54||$1,702.50||1,005,500|| |
|8/21/2017||Christopher U Missling||Insider||Buy||375||$4.07||$1,526.25||1,005,125|| |
|8/18/2017||Christopher U Missling||Insider||Buy||375||$3.81||$1,428.75||1,004,750|| |
|8/14/2017||Christopher U Missling||Insider||Buy||375||$3.70||$1,387.50||1,004,375|| |
|8/11/2017||Christopher U Missling||Insider||Buy||750||$3.55||$2,662.50||1,004,000|| |
|7/14/2015||Christopher U Missling||CEO||Buy||1,000||$0.52||$520.00|| |
|7/13/2015||Christopher U Missling||CEO||Buy||1,000||$0.53||$530.00|| |
|7/7/2015||Christopher U Missling||CEO||Buy||2,000||$0.49||$980.00|| |
|7/1/2015||Christopher U Missling||CEO||Buy||2,000||$0.45||$900.00|| |
|6/23/2015||Christopher U Missling||CEO||Buy||1,000||$0.47||$470.00|| |
|6/22/2015||Christopher U Missling||CEO||Buy||1,000||$0.42||$420.00|| |
|6/16/2015||Christopher U Missling||CEO||Buy||1,000||$0.44||$440.00|| |
|6/15/2015||Christopher U Missling||CEO||Buy||1,000||$0.43||$430.00|| |
|6/10/2015||Christopher U Missling||CEO||Buy||1,000||$0.36||$360.00|| |
|6/8/2015||Christopher U Missling||CEO||Buy||1,000||$0.35||$350.00|| |
|6/4/2015||Christopher U Missling||CEO||Buy||1,000||$0.37||$370.00|| |
Anavex Life Sciences (NASDAQ AVXL) News Headlines
Anavex Life Sciences (NASDAQ:AVXL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Anavex Life Sciences (NASDAQ:AVXL) Income Statement, Balance Sheet and Cash Flow Statement
Anavex Life Sciences (NASDAQ AVXL) Stock Chart for Sunday, February, 25, 2018